¤ OpenAccess: Green

This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal,Monica M. Gomes da Silva,Dany Badibanga Musungaie,Evgeniy Kovalchuk,Antonio González,Vilmania Bello Reyes,Alejandro Martín-Quirós,Yoseph Caraco,Angela Williams‐Diaz,Michelle Brown,Jiejun Du,Alison Pedley,Christopher Assaid,Julie Strizki,Jay A. Grobler,Hala Shamsuddin,Robert Tipping,Hong Wan,Amanda Paschke,Joan R. Butterton,Matthew G. Johnson,Carisa De Anda

Medicine

Coronavirus disease 2019 (COVID-19)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

2022

New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Cite this:

Generate Citation

“Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients” is a paper by Angélica Jayk Bernal Monica M. Gomes da Silva Dany Badibanga Musungaie Evgeniy Kovalchuk Antonio González Vilmania Bello Reyes Alejandro Martín-Quirós Yoseph Caraco Angela Williams‐Diaz Michelle Brown Jiejun Du Alison Pedley Christopher Assaid Julie Strizki Jay A. Grobler Hala Shamsuddin Robert Tipping Hong Wan Amanda Paschke Joan R. Butterton Matthew G. Johnson Carisa De Anda published in 2022. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.